Merial GmbH, Kathrinenhof Research Center, 83101 Rohrdorf, Germany.
8330 Sümeg, Hungary.
Vet Parasitol. 2014 Apr 28;202(1-2):10-7. doi: 10.1016/j.vetpar.2014.02.032.
A novel topical combination product (BROADLINE(®), Merial) composed of fipronil, (S)-methoprene, eprinomectin and praziquantel was evaluated for safety and efficacy against nematode and cestode infections in domestic cats. The study comprised a multi-centre, positive control, blinded, field study, using a randomized block design based on order of presentation for allocation. In total 196 client-owned cats, confirmed as positive for naturally acquired infections of nematodes and/or cestodes by pre-treatment faecal examination, were studied in seven countries in Europe. Pre-treatment faecal examination revealed the presence of Toxocara, hookworm, Capillaria and/or spirurid nematode infections in 129, 73, 33 or 1 cat(s), respectively; infections with taeniid and Dipylidium cestodes were demonstrated in 39 and 17 cats, respectively. Cats were allocated randomly to one of two treatments in a ratio of 2, topical fipronil (8.3%, w/v), (S)-methoprene (10%, w/v), eprinomectin (0.4%, w/v) and praziquantel (8.3%, w/v) (BROADLINE(®), Merial; 130 cats); and 1, topical PROFENDER(®) Spot-On (Bayer; 66 cats) and treated once on Day 0. For evaluation of efficacy, two faecal samples were collected, one prior to treatment (Day -4 ± 4 days) and one at the end of the study (Day 14 ± 5 days). These were examined for fecal forms of nematode and cestode parasites. For evaluation of safety, cats were examined by a veterinarian before treatment and at the end of the study, and cat owners recorded the health status of their cats daily until the end of the study. For cats treated with Broadline(®), the efficacy was >99.9%, 100%, and 99.6% for Toxocara, hookworms, and Capillaria, respectively; and the efficacy was >99.9%, >99.9%, and 98.5%, respectively, for the cats treated with Profender(®) (p<0.001 for all nematodes and both treatments). Efficacy was 100% for both cestodes for both treatments (p<0.001). No treatment related adverse experiences were observed throughout the study. For both treatments, every cat that completed the study was given a safety score of 'excellent' for both local and systemic evaluations. The topical combination product of fipronil, (S)-methoprene, eprinomectin and praziquantel was shown to have an excellent safety profile and demonstrated high levels of efficacy when administered once as topical solution to cats infected with nematodes and cestodes under field conditions.
一种新型的局部联合用药产品(BROADLINE(®),梅里亚),由氟虫腈、(S)-灭幼脲、埃普里诺菌素和吡喹酮组成,用于评估其对患有寄生虫感染的家猫的安全性和疗效。该研究是一项多中心、阳性对照、盲法、现场研究,采用基于呈现顺序的随机分组设计进行分组。在欧洲的七个国家,共有 196 只经过确认患有自然获得性线虫和/或绦虫感染的宠物猫参与了该研究。在治疗前的粪便检查中,有 129 只猫、73 只猫、33 只猫或 1 只猫分别存在感染旋毛虫、钩虫、毛细线虫和/或螺旋线虫的情况;39 只猫和 17 只猫分别存在感染带绦虫和复孔绦虫的情况。这些猫按照 2:1 的比例随机分配到两种治疗方案中,分别是局部应用氟虫腈(8.3%,w/v)、(S)-灭幼脲(10%,w/v)、埃普里诺菌素(0.4%,w/v)和吡喹酮(8.3%,w/v)(BROADLINE(®),梅里亚;130 只猫)和局部应用普罗芳(®)点(拜耳;66 只猫),均在第 0 天接受一次治疗。为了评估疗效,在治疗前(第-4±4 天)和研究结束时(第 14±5 天)收集了两份粪便样本。这些样本被用来检查粪便中的线虫和绦虫寄生虫。为了评估安全性,在治疗前和研究结束时,兽医对猫进行了检查,猫主人每天记录猫的健康状况,直到研究结束。在接受 BROADLINE(®)治疗的猫中,旋毛虫、钩虫和毛细线虫的疗效分别为>99.9%、100%和 99.6%;接受普罗芳(®)治疗的猫的疗效分别为>99.9%、>99.9%和 98.5%(所有线虫和两种治疗方案均有统计学意义,p<0.001)。两种治疗方案对两种绦虫的疗效均为 100%(p<0.001)。整个研究过程中均未观察到与治疗相关的不良事件。对于两种治疗方案,所有完成研究的猫在局部和全身评估中均获得了“优秀”的安全性评分。该氟虫腈、(S)-灭幼脲、埃普里诺菌素和吡喹酮的局部联合用药产品具有极佳的安全性,在现场条件下,作为局部溶液单次给药,对感染线虫和绦虫的猫具有很高的疗效。